Novo Nordisk, monlunabant
Novo Nordisk Sinks on Obesity Drug Study's Disappointing Results
Key Takeaways Novo Nordisk's U.S.-listed shares lost ground Friday after a Phase 2a trial of the pharmaceutical firm’s latest obesity treatment showed less effectiveness in higher doses.Based on the results,
Novo Nordisk shares drop nearly 5% on disappointing obesity pill data
By Maggie Fick and Jacob Gronholt-Pedersen LONDON/COPENHAGEN (Reuters) -Novo Nordisk's shares fell nearly 5% on Friday after results from a Phase 2a trial of the Danish drugmaker's experimental obesity pill monlunabant came in below market expectations.
Novo Nordisk's Monlunabant Data Drags Stocks Of Smaller Players
Novo Nordisk A/S (NYSE:NVO) announced headline results from a phase 2a clinical trial with monlunabant, a small-molecule oral cannabinoid receptor 1 (CB1) inverse agonist. After 16 weeks of treatment,
Novo Nordisk's experimental weight loss pill has some concerning side effects
Ozempic maker Novo Nordisk (NVO) announced mixed results today for a phase 2 trial of an experimental weight loss pill that works differently than its already-popular weight loss drug Wegovy.
High-Flying Novo Nordisk Dips On Disappointing Data for Weight-Loss Pill
Novo Nordisk’s American depositary receipts tumbled almost 6% Friday after the drugmaker reported mixed results from a study of an experimental weight-loss pill. The pill, monlunabant, helped people lose weight in the mid-stage study,
Novo Nordisk Just Took a $530 Million Step Onto Moderna's Turf. Here's What It Means for Both Stocks
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium investing solutions, free guidance and market analysis on Fool.com, top-rated podcasts, and non-profit The Motley Fool Foundation.
Novo Nordisk, Wegovy
Corbus Pharma (CRBP) Stock Drops 60% After Novo Nordisk's Cannabinoid-Based Weight Loss Drug Trial Disappoints
Corbus Pharmaceuticals and Novo Nordisk stocks plunge following cannabinoid receptor drug trials, raising concerns over ...
Novo Nordisk Slips On Phase 2a Clinical Trial Result With Monlunabant
Friday, shares of Novo Nordisk A/S (NVO) are sliding following the announcement of safety results of phase 2a clinical trial of ...
Novo Nordisk: The Street Is Not Seeing The Growth Acceleration Potential
Novo Nordisk A/S's shares have stalled recently, but this looks like a natural digestion of gains from prior years. Click for ...
Novo Nordisk Stock Declines After Headline Results From Mid-Stage Study Of Monlunabant In Obese Patients
Novo Nordisk announced Phase 2a trial results for monlunabant. The trial demonstrated a weight reduction of 7.1 kg with a 10 ...
NJBIZ21h
Novo Nordisk expects Ozempic in next round of Medicare price talks
In August 2023, the U.S. Department of Health and Human Services announced the first 10 drugs covered under Medicare Part D ...
NBC New York10d
Novo Nordisk weight-loss drug is effective for kids as young as 6, study shows
Based on the results of the trial, drugmaker Novo Nordisk has asked U.S. regulators to expand use of the medication for ...
STAT7h
Novo’s new obesity drug shows modest results, raises concerns of psychiatric side effects
A next-generation obesity drug candidate from Novo Nordisk produced modest weight loss, along with a higher rate of some ...
FierceBiotech7h
Novo obesity prospect linked to ‘mild to moderate neuropsychiatric side effects’ in phase 2
In this morning’s readout from Novo's phase 2 trial of monlunabant in 243 people with obesity and metabolic syndrome, it ...